Patents by Inventor Leo Joseph Letendre

Leo Joseph Letendre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION
    Publication number: 20200230256
    Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
    Type: Application
    Filed: March 3, 2020
    Publication date: July 23, 2020
    Applicant: PFIZER INC.
    Inventors: Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
  • Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
    Patent number: 10653794
    Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: May 19, 2020
    Assignee: Pfizer Inc.
    Inventors: Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
  • Intermediates and methods for synthesizing calicheamicin derivatives
    Patent number: 10508081
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: December 17, 2019
    Assignee: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION
    Publication number: 20190030183
    Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
    Type: Application
    Filed: August 9, 2016
    Publication date: January 31, 2019
    Applicant: PFIZER INC.
    Inventors: Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
  • INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES
    Publication number: 20180134656
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: PFIZER INC.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • Intermediates and methods for synthesizing calicheamicin derivatives
    Patent number: 9902691
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: February 27, 2018
    Assignee: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES
    Publication number: 20160251389
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 1, 2016
    Applicant: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang